Today: 1 May 2026
UEC stock today: Uranium Energy jumps 10% as uranium miners rally on Phoenix project update
2 January 2026
1 min read

UEC stock today: Uranium Energy jumps 10% as uranium miners rally on Phoenix project update

NEW YORK, January 2, 2026, 12:34 ET — Regular session

  • Uranium Energy shares rise in midday trading as uranium-linked stocks open 2026 with sharp gains.
  • Peer Denison’s Phoenix project update helps lift sentiment across the uranium group.
  • Investors keep an eye on uranium price indicators and project-permitting milestones.

Uranium Energy Corp shares jumped about 10% in midday trading on Friday, tracking a broad rally in uranium miners at the start of the first U.S. session of 2026.

The stock was up 10.3% at $12.88 after trading between $11.85 and $12.96, with about 4.5 million shares traded.

Sentiment improved after Denison Mines said it was ready to make a final investment decision and begin building its Phoenix in-situ recovery (ISR) uranium mine, pending final federal approvals after a Canadian regulator hearing ended on Dec. 11. “Denison stands ready to make a final investment decision and commence construction of the Phoenix ISR mine,” CEO David Cates said in a statement. PR Newswire

Project updates can move uranium equities fast because the commodity is largely sold via privately negotiated long-term supply contracts rather than an exchange-traded spot market, Cameco says. UEC’s website showed the TradeTech uranium indicator at $81 a pound on Friday, and the company’s latest news release was dated Dec. 10, leaving the shares trading largely on sector headlines.

Other uranium names moved in the same direction. Cameco rose about 7.2%, Energy Fuels gained about 12.0%, Denison’s U.S.-listed shares climbed about 11.3%, and the Global X Uranium ETF advanced about 6.5%.

Denison’s Toronto-listed shares jumped 11.4%, Reuters reported, underscoring how quickly project-readiness headlines can ripple through the sector.

Uranium Energy develops ISR uranium projects in the United States and conventional projects in Canada, according to Reuters. It has ISR “hub-and-spoke” platforms in South Texas and Wyoming anchored by licensed processing plants, with permitted satellite projects intended to feed those hubs. Reuters

In its most recent quarterly update on Dec. 10, UEC said it had $698 million of cash, uranium inventory and equities at market prices and no debt. The company also said it completed a $234 million public offering to support development work, including its planned uranium refining and conversion initiative.

The nuclear-fuel supply chain has also drawn attention in recent days. Urenco USA said it completed a first production run of uranium enriched to 8.5% U-235, a step toward so-called LEU+ fuel used in some newer reactor designs, the Reporter-Telegram reported.

ISR, short for in-situ recovery, extracts uranium by circulating a solution through underground ore and pumping it back to the surface, rather than digging an open pit.

Traders are watching the next round of permitting decisions on development projects and any changes in published uranium indicators, which can swing higher-beta miners. For UEC, investors will look for updates on production ramp and project timelines alongside any shift in how it builds and sells uranium inventory.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:17 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
IBM stock falls as 2026 begins; investors eye jobs data and IBM’s Jan. 28 results
Previous Story

IBM stock falls as 2026 begins; investors eye jobs data and IBM’s Jan. 28 results

XRP Price Near $2 as Wall Street’s $8 Target for 2026 Resurfaces — What’s Driving the Split View
Next Story

XRP Price Near $2 as Wall Street’s $8 Target for 2026 Resurfaces — What’s Driving the Split View

Go toTop